1. Gentamicin Vestibulotoxicity: Further Insights From a Large Clinical Series
- Author
-
John Rutka, Terence S Fu, Ophir Ilan, Wanda Dillon, David D. Pothier, Simon D. Carr, Jerome A. Leis, Wayne L. Gold, Iqbal Mohammed Syed, and Paul Douglas-Jones
- Subjects
medicine.medical_specialty ,Vestibular evoked myogenic potential ,Nephrotoxicity ,Neurotology ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Videonystagmography ,Dosing ,Saccule and Utricle ,030223 otorhinolaryngology ,Retrospective Studies ,medicine.diagnostic_test ,Cumulative dose ,business.industry ,Osteomyelitis ,medicine.disease ,Vestibular Evoked Myogenic Potentials ,Semicircular Canals ,Sensory Systems ,Otorhinolaryngology ,Anesthesia ,Gentamicin ,Neurology (clinical) ,Gentamicins ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
OBJECTIVE To review insights gained from a 21-year experience with gentamicin-induced vestibulotoxicity including differences in vestibulotoxicity between single daily dosing (SDD) and multiple daily dosing (MDD) regimens. STUDY DESIGN Retrospective case series. SETTING Tertiary care center. PATIENTS Patients with gentamicin vestibulotoxicity referred to the Hertz Multidisciplinary Neurotology Clinic between January 1993 and September 2014. INTERVENTION None. MAIN OUTCOME MEASURES Spectrum of vestibular dysfunction measured using videonystagmography, vestibular evoked myogenic potentials, video head impulse testing, and magnetic scleral search coil testing. RESULTS Of 53 patients with gentamicin-induced vestibulotoxicity, 24 received SDD and 29 received MDD treatment. The most common indications for treatment were sepsis, endocarditis, and osteomyelitis. Angular acceleration receptor function (semicircular canals) was more commonly affected than linear acceleration receptor function (otolithic organ of the saccule; 100% vs. 62%). A significant proportion of patients (53%) developed vestibulotoxicity in the absence of nephrotoxicity and 40% experienced vestibulotoxicity in a delayed fashion up to 10 days posttreatment cessation (mean 3.9 ± 0.7). Therapeutic monitoring did not necessarily prevent delayed vestibulotoxicity. Nephrotoxicity was less common for SDD compared with MDD (60% vs. 35%, p = 0.01). However, the SDD group experienced vestibulotoxicity at a lower cumulative dose (6.3 vs. 7.0 g, p = 0.04) and shorter duration of therapy (20.7 vs 29.4 d, p = 0.02). CONCLUSIONS Our study further highlights important insights regarding gentamicin-induced vestibulotoxicity. While SDD is associated with decreased risk for nephrotoxicity compared with MDD, it confers a higher risk for vestibulotoxicity.
- Published
- 2020
- Full Text
- View/download PDF